Daliresp May Ease Lung Inflammation in COPD Patients by Effects on Immune Cells, Trial Data Suggests
The benefits of Daliresp (roflumilast), an approved chronic obstructive pulmonary disease therapy, may include an anti-inflammatory effect, with the treatment seen in a Phase 3 clinical trial to lower the number of eosinophils — a type of immune cell linked to inflammation — in the lungs of patients with moderate to severe…